Nervgen Pharma Shares Outstanding History (NGEN)
Nervgen Pharma reported 79.6M shares outstanding at the end of fiscal 2025.
View full Nervgen Pharma company overviewNervgen Pharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 79.6M | 9.3M | +13.25% |
| 2024 | 2024-12-31 | 70.3M | 10.7M | +18.00% |
| 2023 | 2023-12-31 | 59.6M | 827,323 | +1.41% |
| 2022 | 2022-12-31 | 58.8M | — | — |
Nervgen Pharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 106.4M | 33.6M | +46.10% |
| Q1 2026 | 2026-03-31 | 80.9M | 10.0M | +14.09% |
| Q4 2025 | 2025-12-31 | 79.6M | 9.3M | +13.25% |
| Q3 2025 | 2025-09-30 | 73.4M | — | — |
| Q2 2025 | 2025-06-30 | 72.8M | — | — |
| Q1 2025 | 2025-03-31 | 70.9M | — | — |
| Q4 2024 | 2024-12-31 | 70.3M | — | — |
Nervgen Pharma shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Nervgen Pharma's shares outstanding moved from 58.8M to 79.6M, a change of 20.9M. The latest reported quarter, Q2 2026, shows 106.4M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nervgen Pharma source filings ↗